Department of Medicine, Stanford University, Stanford, California, USA.
Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
JACC Heart Fail. 2024 Aug;12(8):1381-1392. doi: 10.1016/j.jchf.2024.04.002. Epub 2024 Apr 7.
Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss have not been well characterized nationally.
This study aimed to describe contemporary inpatient diuretic practices and clinical predictors of weight loss in patients hospitalized for HF.
The authors identified HF hospitalizations from 2015 to 2022 in a U.S. national database aggregating deidentified patient-level electronic health record data across 31 geographically diverse community-based health systems. The authors report patient characteristics and inpatient weight change as a primary indicator of decongestion. Predictors of weight loss were evaluated using multivariable models. Temporal trends in inpatient diuretic practices, including augmented diuresis strategies such as adjunctive thiazides and continuous diuretic infusions, were assessed.
The study cohort included 262,673 HF admissions across 165,482 unique patients. The median inpatient weight loss was 5.3 pounds (Q1-Q3: 0.0-12.8 pounds) or 2.4 kg (Q1-Q3: 0.0-5.8 kg). Discharge weight was higher than admission weight in 20% of encounters. An increase of ≥0.3 mg/dL in serum creatinine from admission to inpatient peak occurred in >30% of hospitalizations and was associated with less weight loss. Adjunctive diuretic agents were utilized in <20% of encounters but were associated with greater weight loss.
In a large-scale U.S. community-based cohort study of HF hospitalizations, estimated weight loss from inpatient decongestion remains highly variable, with weight gain observed across many admissions. Augmented diuresis strategies were infrequently used. Comparative effectiveness trials are needed to establish optimal strategies for inpatient decongestion for acute HF.
心力衰竭(HF)是美国住院的主要原因。 去充血仍然是住院管理的核心目标,但目前的去充血实践和相关的体重减轻尚未得到很好的描述。
本研究旨在描述心力衰竭住院患者目前的住院利尿剂治疗方法和体重减轻的临床预测因素。
作者在美国一个全国性数据库中确定了 2015 年至 2022 年的 HF 住院患者,该数据库汇总了 31 个地理位置不同的社区基础医疗系统的匿名患者级电子健康记录数据。作者报告了患者特征和住院期间的体重变化,作为去充血的主要指标。使用多变量模型评估体重减轻的预测因素。评估了住院期间利尿剂治疗方法的时间趋势,包括辅助利尿剂策略,如辅助噻嗪类药物和连续利尿剂输注。
研究队列包括 262673 例 HF 住院患者,涉及 165482 例独特患者。住院期间体重减轻中位数为 5.3 磅(Q1-Q3:0.0-12.8 磅)或 2.4 公斤(Q1-Q3:0.0-5.8 公斤)。20%的就诊中出院体重高于入院体重。入院至住院高峰时血清肌酐增加≥0.3mg/dL的情况发生在超过 30%的住院患者中,与体重减轻较少有关。辅助利尿剂在<20%的就诊中使用,但与体重减轻更多相关。
在一项针对美国社区为基础的 HF 住院患者的大规模队列研究中,估计的住院去充血体重减轻仍然高度可变,许多住院患者体重增加。增强的利尿策略很少使用。需要进行比较有效性试验,以确定急性 HF 住院患者去充血的最佳策略。